Are SOFT and TEXT results practice changing and how?

- Pagani, Olivia, Regan, Meredith M., Francis, Prudence A.

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

- Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert

Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II

- Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., Cuzick, J.

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

- Saura, Christina, Oliveira, Mafalda, Hlauschek, Dominik, Zardavas, Dimitrios, Jallitsch-Halper, Anita, de la Peña, Lorena, Nuciforo, Paolo, Ballestrero, Alberto, Dubsky, Peter, Lombard, Janine M., Vuylsteke, Peter, Castaneda, Carlos A., Colleoni, Marco, Santos Borges, Giuliarno, Ciruelos, Eva, Fornier, Monica, Boer, Katalin, Bardia, Aditya, Wilson, Timothy R., Stout, Thomas J.

Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer

- de Boer, Richard, Hui, Rina, Lim, Elgene, Yeo, Belinda, Zdenkowski, Nicholas

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

- Francis, Prudence A., Pagani, Olivia, Bennefoi, Herve R., Bellet, Meritxell, Martino, Silvana, Geyer, Jr., Charles E., Goetz, Matthew P., Stearns, Vered, Pinotti, Graziella, Puglisi, Fabio, Spazzapan, Simon, Climent, Miguel A., Fleming, Gini F., Pavesi, Lorenzo, Ruhstaller, Thomas, Davidson, Nancy E., Coleman, Robert, Debled, Marc, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Maibach, Rudolf, Rabaglio-Poretti, Manuela, Walley, Barbara A., Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Regan, Meredith M., Colleoni, Marco, Lang, Istvan, Gomez, Henry L., Tondini, Carlo, Ciruelos, Eva, Burstein, Harold J.